---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-039976"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2022-07-18T23:59:59+00:00"
generated_at: "2026-06-24T13:10:44.555664+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Protara Therapeutics appoints Hannah Fry as Controller and CEO as principal financial officer after CFO departure

## Summary
- Blaine Davis departed as CFO on July 15, 2022.
- Hannah Fry appointed Controller effective July 16, 2022, with $255,000 base salary and 25,000 RSU award.
- CEO Jesse Shefferman appointed as principal financial officer of the company.
- Fry's severance includes six months base salary and pro-rata equity vesting on certain awards.
- Fry previously served as Senior Director, Assistant Controller at Protara.

## SEC filing metadata
- accession: 0001213900-22-039976
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2022-07-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390022039976/0001213900-22-039976-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390022039976/ea162974-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-039976
- JSON: https://secwatch.observer/filing/0001213900-22-039976.json
- Plain text: https://secwatch.observer/filing/0001213900-22-039976.txt

## Key facts
- Executive change
  Blaine Davis departed as Chief Financial Officer at Protara Therapeutics, Inc..
  - Action: left
  - Role: Chief Financial Officer
  source text: Protara Therapeutics, Inc. (the “Company”) announced that Blaine Davis, the Chief Financial Officer of the Company, left the Company to pursue other opportunities on July 15, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1359931/000121390022039976/0001213900-22-039976-index.htm
- Executive change
  Hannah Fry was appointed as Controller at Protara Therapeutics, Inc..
  - Action: appointed
  - Role: Controller
  source text: Effective July 16, 2022 (the “Effective Date”), Hannah Fry has been appointed to the role of Controller of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1359931/000121390022039976/0001213900-22-039976-index.htm
- Executive change
  Jesse Shefferman was appointed as principal financial officer at Protara Therapeutics, Inc..
  - Action: appointed
  - Role: principal financial officer
  source text: Also effective July 16, 2022, Mr. Shefferman has been appointed as principal financial officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1359931/000121390022039976/0001213900-22-039976-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.